EUpolicy

Market Access

European biopharma at a crossroads

If Europe can bridge its operational gaps while leveraging its scientific base, it can carve out a distinctive and sustainable leadership position.

Market Access

US currency with injection needles and pills on top, against orange background

US pharma MFN and tariff dynamics: What EU and UK leaders ne...

Europe and the United Kingdom are entering a period of direct exposure to US policy choices, and the implications are significant and immediate.

News

A globe atlas from above on a white surface

Novartis issues a life sciences warning in a 'G-Zero' world

Novartis claims life sciences lie at the centre of a shift in geopolitics and policies in regions like Europe, Japan, and Canada are "self-defeating."

News

EMA and FDA agree 'principles' for AI in drug development

The FDA and EMA have come up with guiding principles that they say will underpin future guidance on the use of AI technologies in drug development.

Market Access

ISPOR Glasgow with EVERSANA: Perspectives on JCA, PICO, and ...

At ISPOR EU 2025, a cross-stakeholder panel addressed how Joint Clinical Assessment under the EU HTA Regulation is reshaping evidence strategies.

R&D

Europe has the tools to fight superbugs. Let’s use them.

Data shows countries are off track – increasing the risk of profound health and economic consequences from AMR. Medical technologies can help.

European biopharma at a crossroads

US pharma MFN and tariff dynamics: What EU and UK leaders ne...

Novartis issues a life sciences warning in a 'G-Zero' world

EMA and FDA agree 'principles' for AI in drug development

ISPOR Glasgow with EVERSANA: Perspectives on JCA, PICO, and ...

Europe has the tools to fight superbugs. Let’s use them.

NHS "isn't delivering equitable care for rare diseases"

Using AI-driven synthetic personas to take your insights fur...

EUpolicy

Editor's Picks